Hepatocellular carcinoma (HCC) is one of the most malignant tumors worldwide and HCC
patients often develop drug resisitene. Long non-coding RNAs (LncRNAs) are closely …

Multitargeted kinase inhibitors (MKIs) including sorafenib and lenvatinib, are applied for first-
line treatment for inoperable hepatocellular carcinoma (HCC) patients, but the therapeutic …

Chemotherapy resistance is still a key hurdle in current hepatocellular carcinoma (HCC)
treatment. Therefore, clarifying the molecular mechanisms contributing to this acquired …

Purpose Lenvatinib is a long-awaited alternative to Sorafenib for first-line targeted therapy of
patients with advanced hepatocellular carcinoma (HCC). However, resistance to Lenvatinib …

Sorafenib is the first‑line treatment for advanced hepatocellular carcinoma (HCC). Since
many HCC patients experience drug resistance, there is an urgent need to discover more …

A growing body of evidence indicates that long non‑coding RNAs (lncRNAs) play crucial
roles in the chemoresistance of human cancers. However, the molecular mechanisms …

Hepatocellular carcinoma (HCC) is one of the most death-related cancers worldwide.
Identifying cancer-associated genes and uncovering the vital molecular mechanisms of …

Background The long non-coding RNAs (lncRNAs) have participated in the promotion of
hepatocellular carcinoma (HCC) initiation and progression. Nevertheless, the biological role …

Background and aims Sorafenib is a major nonsurgical option for patients with advanced
hepatocellular carcinoma (HCC); however, its clinical efficacy is largely undermined by the …

Increasing evidence has demonstrated that abnormal expression of lncRNA is correlated
with various malignant tumors, including hepatocellular carcinoma (HCC). Our current study …